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Abstract Two masked cysteine residues have been reported in 
methylmalonyl-CoA mutase from Propionibacterium shermanii, 
Cys-535 in the c¢-subunit and Cys-517 in the ~-subunit, which are 
revealed only after reduction of the denatured enzyme with 
dithiothreitol. It has been postulated that these residues are 
involved in disulphide linkages to unknown thiols of low Mr. 
These two masked cysteine residues have been changed to an 
alanine, individually. Both the mutants, C535ff.A and C517[~A, 
were inactive. This shows that both these residues are essential 
for catalytic activity. 
Key words: Masked cysteine residue; Methylmalonyl-CoA 
mutase 
1. Introduction 
Methylmalonyl-CoA mutase (EC 5.4.99.2) (MCM) is an 
adenosylcobalamin-dependent enzyme that catalyses the inter- 
conversion of succinyl-CoA (3-carboxypropionyl-CoA) and 
(2R)-methylmalonyl-CoA, both in mammalian liver [1] and 
in the propionate-producing fermentation of certain bacteria 
such as Propionibacterium shermanii [2,3]. 
MCM from P. shermanii is a dimer consisting of an c~-sub- 
unit (Mr 79000) and a ~-subunit (Mr 67000) [4]. The struc- 
tural genes have been cloned and sequenced [5], and co-ex- 
pressed in Escherichia coli [6]. The apoenzyme purified from 
the recombinant E. coli can be converted into active holoen- 
zyme by addition of adenosylcobalamin [6]. The amino acid 
sequence for P. shermanii MCM deduced from the sequence 
of the structural genes shows that the [~-subunit contains four, 
and the e~-subunit contains two cysteine residues. However, 
treatment of the denatured enzyme with iodo[l~C]acetic acid 
resulted in only four moles of 14C label being incorporated per 
mole of mutase [7]. Pretreatment of the denatured enzyme 
with dithiothreitol before treatment with iodo[HC]acetic acid 
resulted in six moles of a4C label being incorporated per mole 
of mutase. SDS/polyacrylamide-gel lectrophoresis in the 
presence and absence of dithiothreitol shows no inter-subunit 
disulphide bond is present in the denatured enzyme. This 
ruled out the possibility of the masked thiols being involved 
in inter-subunit disulphide linkage. Also, hydroxylamine treat- 
ment was not able to unmask the thiol groups, showing that 
these residues were not involved in thioester linkages either. 
These observations indicated that the masked thiols were in- 
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volved in disulphide linkages with thiols of low M,,. Evidence 
was also obtained that a volatile thiol was released by dithio- 
threitol treatment which was trapped using HgC12. The 
masked thiols were found to be located at Cys-535(c0 and 
Cys-517(13) [7]. Furthermore, these thiols were found to occu- 
py exactly equivalent positions in the mutually homologous c~- 
and [3-subunits. This further indicates that these residues have 
similar environments in the native protein [7]. 
Recently the crystal structure of the holoenzyme along with 
desulphoCoA has been determined at 2A resolution [8]. In the 
structure it is found that these thiols are part of the linker 
region which encloses the N-terminal barrel domain and con- 
nects it to the C-terminal domain in each subunit. The residue 
Cys-535 in the c~-subunit is however not found in the de- 
scribed active site, though the present structure lacks both 
the adenosyl group of the cofactor and the rearranged part 
of the substrate. Hence, a detailed description of the active 
site is awaited for which further structures of substrate and 
inhibitor complexes are required. 
This work describes the site-directed mutagenesis of these 
masked thiols and the effect of these changes on the enzyme. 
2. Materials and methods 
2. l. Plasmids, phage and oligonucleotides 
The pUC18 and pUCI9 vectors, pUCll8 and pUC119 vectors, the 
phagemid pTZ18R, and the M13mpl8 and Ml3mpl9 sequencing 
vectors were obtained from Pharmacia (UK) Ltd. The dual plasmid 
pT7-7 expression system was the kind gift of Dr. S. Tabor, Harvard 
Medical School. Helper phage VCSM13 was supplied by Stratagene 
Inc. (San Diego, CA, USA) as part of their 'Bluescript' cloning and 
sequencing system. The pTZ18R-based double mutant plasmid 
pM7mut3, containing the P. shermanii MCM genes with an NdeI 
site at the start codon for the upstream [3-subunit, and with the start 
codon for the c~-subunit altered from GTG to ATG, has been de- 
scribed previously [6]. 
The oligonucleotides used for site-directed mutagenesis and se- 
quencing were synthesised on a Millipore Biosearch Cyclone auto- 
mated synthesiser by Mike Weldon of the Wellcome Trust-funded 
oligonucleotide synthesis ervice in the Department of Biochemistry, 
University of Cambridge. 
2.2. Bacterial strains 
E. coli TGlrecO [9] was from Dr. P. Oliver, Department of Genet- 
ics, University of Cambridge. E. coli K38 [K12, HfrC, ()~)] containing 
the plasmid pGP1-2 was from Dr S. Tabor, Harvard Medical School. 
The pGP1-2 plasmid contains a heat-inducible gene for T7 RNA 
polymerase [10]. The E. coli NM538 [supF, hsdR, trpR, lacY] [11] 
was from Dr D.M. Carrington, Department of Biochemistry, Univer- 
sity of Cambridge. E. coli TGlrecO was stored on M9 minimal med- 
ium agar plates [12] to maintain selection for the F' episome. The 
other E. coli strains were grown or maintained on 2TY agar plates 
or liquid medium with antibiotic supplements a  required for plasmid 
selection. Media constituents were from either Oxoid (Basingstoke, 
UK) or Lab M (Bury, UK). Yeast extract was from Beta-lab (East 
Molesey, UK). 
All rights reserved. 
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Fig. 1. Construction of the overexpression plasmid for the C535c~A 
and C51713A mutants. 
2.3. Site-directed mutagenesis 
The phagemid pMTmut3 [6] was used for in vitro mutagenesis, 
using the phosphorothioate method [13]. Single-stranded DNA was 
produced by superinfection of cells containing pM7mut3 with the 
helper phage VCSM13. The oligonucleotide designed to achieve the 
mutation of Cys-517 (13) to alanine was the 20-mer: 5'- 
TTCCTGGCCGCCTTGGGCAC-3'  and that of Cys-535 (c0 to ala- 
nine was the 20-mer: 5'-CTGAAGCTGGCCATCGACGC-3'.  These 
were purified by gel electrophoresis, and 5'-phosphorylated. These 
oligonucleotides (5 pmole) were next annealed to 5 ~tg template by 
heating for 3 min to 70°C followed by slow cooling to room tempera- 
ture. The mutagenesis was carried out using the Amersham in vitro 
mutagenesis kit (version 2) according to the supplier's instructions. 
The mutant homoduplexes synthesised were used to transform E. 
~oli TGlrecO to ampicillin resistance. For each mutant, phagemid 
was recovered from eight recombinant colonies and characterised by 
DNA sequencing using the dideoxy chain termination method, to 
show that the desired change had been accomplished. One of each 
mutant phagemid was selected for further work, and designated as 
pMC517A and pMC535A (Fig. 1). Subsequently, a set of primers was 
used to re-sequence in their entirety the structural genes for both 
MCM structural genes. No additional unwanted alterations were 
found. 
and HindIII and the resulting NdeI-HindlII fragment were gel-purified 
and ligated into appropriately digested, phosphatase-treated pT7-7 
[6,10] and the ligation mixture was transformed into E. coli TGlrecO. 
Heat shock during transformation was done at 30°C for 5 min, to 
avoid induction of MCM expression. Ampicillin-resistant colonies 
were picked and screened for the presence of the plasmid containing 
the NdeI-HindlII fragment. These expression plasmids, termed 
pMEX2 C517~3A and pMEX2 C535~A (Fig. 1), were transformed 
into £ coil K381pGP1-2 [6,10] for expression of the mutant mutase 
genes, and transformants were selected after overnight growth at 30°C 
on 2TY agar plates supplemented with ampicillin (100 lag/ml) and 
kanamycin (60 ~g/ml). For large-scale growth of the strains contain- 
ing the expression plasmid, five 2-1itre flasks, each containing 600 ml 
of 2TY medium (100 l.tg/ml ampicillin, 60 lttg/ml kanamycin) were 
inoculated with an overnight culture (3.5 ml) and incubated at 38°C 
until the A600 reached 1.5. Fresh 2TY medium (400 ml), pre-heated to 
65°C, was then added to each flask which was shaken for 1 min. The 
flasks were then chilled quickly on ice and incubated for a further 2.5 
h at 28°C. The cells were harvested by centrifugation and the paste 
was stored at -70°C. 
2.5. Partial purification of the mutant proteins 
Partial purification of the mutant proteins was carried out using ion 
exchange chromatography. The cells were broken by sonication using 
a tip sonicator operated at 90% of full power output, in cold 100 mM 
Tris-HCl pH 7.5 containing 5 mM benzamidine hydrochloride, 0.5 
mM phenylmethanesulphonyl fluoride and 2 mM dithiothreitol. The 
sonication was done in bursts of 2 min, at intervals of 10 min with 
cooling on ice, until a clearing of the protein solution was observed. 
Finally the cell debris was removed by centrifugation at 12000×g at 
4°C for 30 min. The supernatant was diluted with an equal volume of 
water and was loaded onto a 300 ml Q-Sepharose column. A 1-1itre 
gradient of 0-0.6 M KC1 in 50 mM Tris-HC1 buffer pH 7.5 containing 
0.2 mM DTT and a flow rate of 180 ml/h was used to elute the 
mutant mutases. None of the mutants had any detectable activity. 
2.6. Measurement of MCM activity 
Measurements of MCM activity were carried out at 30°C and pH 
7.5 using a continuous pectrophotometric assay in which the produc- 
tion of (2R)-methylmalonyl-CoA is coupled to NADH oxidation by 
malate dehydrogenase [6,14]. 
3. Results and discussion 
We have changed both  the masked thiol residues into ala- 
GAT C 
Ala 
535 '~  
Cys 
535 
2.4. High level expression of the mutant MCM genes Fig. 2. DNA sequencing el showing the cysteine to alanine substi- 
The plasmids pMC517A and pMC535A were digested with NdeI tution brought about in the C535e~A mutant. 
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Fig. 3. A Coomassie blue-stained 15'¼, SDS polyacrylamide gel 
showing the overexpression f the C535~A mutant. 1. Purified wild 
type P. shermanii MCM. 2. Whole cell extract of E. coli K38/pGP1- 
2 containing pMEX2 C535otA, induced. 3. Soluble fraction of the 
whole cell extract of E. coli K38/pGP1-2 containing pMEX2 
C535e~A, induced. 4. Insoluble fraction of the whole cell extract of 
E. coli K38/pGP1-2 containing pMEX2 C535e~A, induced. M: High 
molecular weight markers. 
nine, individually (Fig. 2 shows the cysteine to alanine sub- 
stitution brought about in C535o~A). Both these mutant pro- 
teins have been successfully overexpressed using the pT7-7/ 
pGPI-2 dual plasmid expression system [10] (Fig. 3 shows 
the overexpression of the C535otA mutant). This indicates 
that both the mutants are stably folded. 
Partial purification of the mutant enzymes was carried out 
to remove the NADH oxidase activity in the presence of 
which the coupled assay [14] cannot be used. Both the mutant 
proteins were successfully purified so as to remove the unde- 
sirable NADH oxidase activity. Activity measurements on 
these partially purified enzymes indicated that in both the 
mutants, enzyme activity had been abolished. These masked 
thiol residues form a part of the linker region. The residue in 
the e~-subunit, Cys-535, is not involved in cobalamin binding 
or in substrate binding. It is also not necessarily directly in- 
volved in the formation of the active site. Hence the total loss 
of activity on its substitution with alanine indicates that it 
plays an extremely important role in the proper folding of 
the active-site region. Also, the ~-subunit has no obvious ma- 
jor function although it contributes one residue to the sub- 
strate binding site. However, it has been observed that the c~- 
subunit when expressed on its own is unable to fold (Dr. M. 
Patchett and Dr. N. McKie, personal communication). Hence, 
the [~-subunit definitely plays a major role in the stable folding 
of the ~-subunit. The total loss of activity on the substitution 
of the Cys-517 residue indicates that it plays a very important 
role in the correct folding of the ~-subunit and hence the c~- 
subunit. However, the absolute structural role of these thiols 
will have to be confirmed using the structure of MCM con- 
taining the intact substrate molecule. In conclusion, this work 
shows that the masked thiols play an essential role in the 
catalysis of P. shermanii MCM by direct or indirect involve- 
ment in the active site formation (Cys-535c0 and the correct 
folding of the ~-[3 heterodimer (Cys-517~3). 
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